BLUEJET

: Growth Strategy and Valuation Correction

→ Blue Jet Healthcare Ltd's stock has dropped nearly 40% from its 52-week high of ₹1,027.80 .The major trigger for the stock correction was a decline in its EBITDA margin to 34% in Q1FY26 from 41% in Q4FY25, mainly attributed to inventory adjustments and minor changes in the product mix. → The company is a key player in contract manufacturing, specializing in niche areas with high entry barriers, and serves major global clients. Its business portfolio includes contrast media intermediates for diagnostic imaging, supplied to companies like GE Healthcare, Guerbet Group, and Bracco Imaging. → Blue Jet also manufactures high-intensity sweeteners (e.g., saccharin) for clients like Colgate-Palmolive and Unilever, in addition to specialty pharmaceutical ingredients and Active Pharmaceutical Ingredients (APIs). → A core strategy is "moving up the value chain": in contrast media, the firm is transitioning from simple building blocks to more complex, advanced intermediates, thereby capturing higher value per molecule. → To further boost margins, the company is undertaking backward integration at its Mahad facility by constructing a plant to produce a previously imported starting material, which is expected to be operational in H2FY26. → In the pharma intermediates and APIs segment, the focus is on high-margin projects in chronic therapy areas such as cardiovascular, oncology, and CNS. This strategy led to the segment's revenue growing over four times in FY25, largely driven by a cardiovascular intermediate developed with an innovator client. → The firm has demonstrated strong historical performance, with revenue and profit after tax (PAT) more than doubling over four years (FY21-FY25), from ₹499 crore to ₹1,030 crore and ₹140 crore to ₹305 crore, respectively. → Blue Jet has quadrupled its capacity in the last four years and plans to add another 1,000KL capacity to support its medium-term growth objectives, backed by strong client commitments.